{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T02:10:51Z","timestamp":1781921451962,"version":"3.54.5"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T00:00:00Z","timestamp":1723075200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Although topical agents have been used to treat cutaneous lupus erythematosus (CLE), there was previously no high-quality evidence of which agents were most effective and which clinical scores were most suitable.<\/jats:p>\n               <jats:p>On 22 December 2023, a search was conducted across five databases to identify randomized controlled trials (RCTs) for CLE. Two authors independently screened the titles and abstracts of articles based on predetermined criteria. Selected articles were then assessed for inclusion in a blinded manner, with any disagreements resolved through consensus. Data were abstracted in duplicate, and a random-effects model was utilized for network meta-analysis. The certainty of the evidence was evaluated according to the PRISMA guidelines, using the GRADE approach. The analysis was finalized in January 2024, with the primary outcome focused on the change in Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) from baseline.<\/jats:p>\n               <jats:p>Seven RCTs involving 231 participants were analysed. The network meta-analysis revealed that nicotinamide 4% demonstrated the highest probability of achieving the intended outcomes, with a mean difference (MD) of 3.10 and a 95% confidence interval (CI) of 1.99\u20134.21. Additionally, clobetasol 0.05%, nicotinamide 2% and tacrolimus 0.1% also exhibited statistically significant differences, with MDs of 2.30 (95% CI of 0.73\u20133.88), 2.30 (95% CI 0.97\u20133.63) and 1.30 (95% CI 0.03\u20132.57), respectively.<\/jats:p>\n               <jats:p>This NMA demonstrates with a high level of evidence that nicotinamide 4%, clobetasol 0.05%, nicotinamide 2% and tacrolimus 0.1% are statistically significant topical agents for CLE. CLASI may be an appropriate outcome to evaluate drug efficacy in CLE.<\/jats:p>","DOI":"10.1093\/ced\/llae236","type":"journal-article","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T19:52:46Z","timestamp":1723146766000},"page":"21-28","source":"Crossref","is-referenced-by-count":3,"title":["Efficient topical treatments of cutaneous lupus erythematosus: a systematic review and network \u00admeta-analysis"],"prefix":"10.1093","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6093-1881","authenticated-orcid":false,"given":"Takemichi","family":"Fukasawa","sequence":"first","affiliation":[{"name":"Department of Dermatology, Systemic Sclerosis Centre, The University of Tokyo Graduate School of Medicine , Tokyo ,","place":["Japan"]},{"name":"Department of Clinical Cannabinoid Research, The University of Tokyo Graduate School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asako","family":"Yoshizaki-Ogawa","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Systemic Sclerosis Centre, The University of Tokyo Graduate School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Enomoto","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Radiology, Center for Disease Biology and Integrative Medicine, The University of Tokyo Graduate School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Miyagawa","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Radiology, Center for Disease Biology and Integrative Medicine, The University of Tokyo Graduate School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Systemic Sclerosis Centre, The University of Tokyo Graduate School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8194-9140","authenticated-orcid":false,"given":"Ayumi","family":"Yoshizaki","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Systemic Sclerosis Centre, The University of Tokyo Graduate School of Medicine , Tokyo ,","place":["Japan"]},{"name":"Department of Clinical Cannabinoid Research, The University of Tokyo Graduate School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,8]]},"reference":[{"key":"2024122223541749700_llae236-B1","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1001\/archderm.138.9.1175","article-title":"Frequency and severity of systemic disease in patients with subacute cutaneous lupus erythematosus","volume":"138","author":"Black","year":"2002","journal-title":"Arch Dermatol"},{"key":"2024122223541749700_llae236-B2","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.autrev.2017.05.009","article-title":"Pathogenesis of cutaneous lupus erythema associated with and without systemic lupus erythema","volume":"16","author":"Zhang","year":"2017","journal-title":"Autoimmun Rev"},{"key":"2024122223541749700_llae236-B3","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.reuma.2022.11.005","article-title":"Cutaneous manifestations in patients with systemic lupus erythematosus: forms at the beginning of the disease and during follow-up. Retrospective analysis","volume":"19","author":"Cosentino","year":"2023","journal-title":"Reumatol Clin (Engl Ed)"},{"key":"2024122223541749700_llae236-B4","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jid.2018.08.017","article-title":"Advances in cutaneous lupus erythematosus and dermatomyositis: a report from the 4th International Conference on Cutaneous Lupus Erythematosus \u2013 an ongoing need for international consensus and collaborations","volume":"139","author":"Concha","year":"2019","journal-title":"J Invest Dermatol"},{"key":"2024122223541749700_llae236-B5","doi-asserted-by":"crossref","first-page":"916134","DOI":"10.3389\/fmed.2022.916134","article-title":"Influence of socio-demographic factors in patients with cutaneous lupus erythematosus","volume":"9","author":"Walker","year":"2022","journal-title":"Front Med"},{"key":"2024122223541749700_llae236-B6","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/0738-081X(85)90078-1","article-title":"Subacute cutaneous lupus erythematosus","volume":"3","author":"Sontheimer","year":"1985","journal-title":"Clin Dermatol"},{"key":"2024122223541749700_llae236-B7","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0190-9622(86)70295-8","article-title":"Subacute cutaneous lupus erythematosus. Clinical, serologic, and immunogenetic studies of forty-nine patients seen in a nonreferral setting","volume":"15","author":"Callen","year":"1986","journal-title":"J Am Acad Dermatol"},{"key":"2024122223541749700_llae236-B8","doi-asserted-by":"crossref","first-page":"6579","DOI":"10.3390\/ijms23126579","article-title":"Pharmacotherapy of itch-antihistamines and histamine receptors as G protein-coupled receptors","volume":"23","author":"Fukasawa","year":"2022","journal-title":"Int J Mol Sci"},{"key":"2024122223541749700_llae236-B9","doi-asserted-by":"crossref","first-page":"5947","DOI":"10.1038\/s41467-021-26099-w","article-title":"Interleukin-31 promotes fibrosis and T helper 2 polarization in systemic sclerosis","volume":"12","author":"Kuzumi","year":"2021","journal-title":"Nat Commun"},{"key":"2024122223541749700_llae236-B10","doi-asserted-by":"crossref","first-page":"e67209","DOI":"10.7554\/eLife.67209","article-title":"Single-cell-level protein analysis revealing the roles of autoantigen-reactive B lymphocytes in autoimmune disease and the murine model","volume":"10","author":"Fukasawa","year":"2021","journal-title":"Elife"},{"key":"2024122223541749700_llae236-B11","doi-asserted-by":"crossref","first-page":"e546","DOI":"10.1016\/S2665-9913(22)00131-X","article-title":"Safety and efficacy of rituximab in systemic sclerosis (DESIRES): open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial","volume":"4","author":"Ebata","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"2024122223541749700_llae236-B12","doi-asserted-by":"crossref","first-page":"7200","DOI":"10.1039\/C9AN01702J","article-title":"Cytokine analysis on a countable number of molecules from living single cells on nanofluidic devices","volume":"144","author":"Nakao","year":"2019","journal-title":"Analyst"},{"key":"2024122223541749700_llae236-B13","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1002\/art.40164","article-title":"Contribution of soluble forms of programmed death 1 and programmed death ligand 2 to disease severity and progression in systemic sclerosis","volume":"69","author":"Fukasawa","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2024122223541749700_llae236-B14","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1093\/rheumatology\/kead287","article-title":"Impact of guselkumab on three cases of SSc accompanying psoriasis","volume":"63","author":"Fukasawa","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2024122223541749700_llae236-B15","doi-asserted-by":"crossref","first-page":"b2700","DOI":"10.1136\/bmj.b2700","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration","volume":"339","author":"Liberati","year":"2009","journal-title":"BMJ"},{"key":"2024122223541749700_llae236-B16","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"2024122223541749700_llae236-B17","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1111\/j.1365-2230.2008.03138.x","article-title":"Pimecrolimus 1% cream versus betamethasone 17-valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double-blind, randomized pilot study","volume":"34","author":"Barikbin","year":"2009","journal-title":"Clin Exp Dermatol"},{"key":"2024122223541749700_llae236-B18","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.jaad.2004.01.044","article-title":"Pimecrolimus 1% cream for cutaneous lupus erythematosus","volume":"51","author":"Kreuter","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"2024122223541749700_llae236-B19","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1093\/rheumatology\/kei093","article-title":"Pimecrolimus 1% cream for the treatment of discoid lupus erythematosus","volume":"44","author":"Tlacuilo-Parra","year":"2005","journal-title":"Rheumatology (Oxford)"},{"key":"2024122223541749700_llae236-B20","doi-asserted-by":"crossref","first-page":"e14675","DOI":"10.1111\/dth.14675","article-title":"Comparison of effectiveness of topical tacrolimus 0.1% versus topical halobetasol propionate 0.05% as an add-on to oral hydroxychloroquine in discoid lupus erythematosus","volume":"34","author":"Barua","year":"2021","journal-title":"Dermatol Ther"},{"key":"2024122223541749700_llae236-B21","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2230.2009.03351.x","article-title":"Efficacy of topical tacrolimus 0.3% in clobetasol propionate 0.05% ointment in therapy-resistant cutaneous lupus erythematosus: a cohort study","volume":"35","author":"Madan","year":"2010","journal-title":"Clin Exp Dermatol"},{"key":"2024122223541749700_llae236-B22","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1002\/jcph.537","article-title":"Tacrolimus 0.03% ointment in labial discoid lupus erythematosus: a randomized, controlled clinical trial","volume":"55","author":"Wang","year":"2015","journal-title":"J Clin Pharmacol"},{"key":"2024122223541749700_llae236-B23","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1365-2133.2006.07595.x","article-title":"Tacrolimus vs. clobetasol propionate in the treatment of facial cutaneous lupus erythematosus: a randomized, double-blind, bilateral comparison study","volume":"156","author":"Tzung","year":"2007","journal-title":"Br J Dermatol"},{"key":"2024122223541749700_llae236-B24","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jaad.2010.03.037","article-title":"Efficacy of tacrolimus 0.1% ointment in cutaneous lupus erythematosus: a multicenter, randomized, double-blind, vehicle-controlled trial","volume":"65","author":"Kuhn","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"2024122223541749700_llae236-B25","first-page":"933","article-title":"A comparative study in efficacy and safety of 0.1% tacrolimus and 0.05% clobetasol propionate ointment in discoid lupus erythematosus by modified Cutaneous Lupus Erythematosus Disease Area and Severity Index","volume":"95","author":"Pothinamthong","year":"2012","journal-title":"J Med Assoc Thai"},{"key":"2024122223541749700_llae236-B26","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1111\/j.1365-2133.2009.09330.x","article-title":"A randomized controlled trial of R-salbutamol for topical treatment of discoid lupus erythematosus","volume":"161","author":"Jemec","year":"2009","journal-title":"Br J Dermatol"},{"key":"2024122223541749700_llae236-B27","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/bjd.16337","article-title":"Computerized planimetry to assess clinical responsiveness in a phase II randomized trial of topical R333 for discoid lupus erythematosus","volume":"178","author":"Presto","year":"2018","journal-title":"Br J Dermatol"},{"key":"2024122223541749700_llae236-B28","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1111\/exd.14253","article-title":"Safety, pharmacokinetics and pharmacodynamics of a topical SYK inhibitor in cutaneous lupus erythematosus: a double-blind phase Ib study","volume":"30","author":"Walker","year":"2021","journal-title":"Exp Dermatol"},{"key":"2024122223541749700_llae236-B29","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1111\/jocd.15628","article-title":"Topical niacinamide (nicotinamide) treatment for discoid lupus erythematosus (DLE): a prospective pilot study","volume":"22","author":"Nouh","year":"2023","journal-title":"J Cosmet Dermatol"},{"key":"2024122223541749700_llae236-B30","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/j.0022-202X.2005.23889.x","article-title":"The CLASI (Cutaneous LE Disease Area and Severity Index): an outcome instrument for cutaneous lupus erythematosus","volume":"125","author":"Albrecht","year":"2005","journal-title":"J Invest Dermatol"},{"key":"2024122223541749700_llae236-B31","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1159\/000359974","article-title":"Niacinamide \u2013 mechanisms of action and its topical use in dermatology","volume":"27","author":"Wohlrab","year":"2014","journal-title":"Skin Pharmacol Physiol"},{"key":"2024122223541749700_llae236-B32","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1039\/b9pp00146h","article-title":"Photoprotective effects of nicotinamide","volume":"9","author":"Damian","year":"2010","journal-title":"Photochem Photobiol Sci"},{"key":"2024122223541749700_llae236-B33","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jaad.2020.03.075","article-title":"No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis","volume":"83","author":"Paller","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2024122223541749700_llae236-B34","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jaad.2023.02.061","article-title":"Interleukin-17 pathway inhibition with brodalumab in early systemic sclerosis: analysis of a single-arm, open-label, phase 1 trial","volume":"89","author":"Fukasawa","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2024122223541749700_llae236-B35","doi-asserted-by":"crossref","first-page":"2418","DOI":"10.1093\/rheumatology\/keac664","article-title":"Utility of nailfold capillary assessment for predicting psoriatic arthritis based on a prospective observational cohort study","volume":"62","author":"Fukasawa","year":"2023","journal-title":"Rheumatology (Oxford)"},{"key":"2024122223541749700_llae236-B36","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.jaad.2023.07.1014","article-title":"Utility of nailfold capillary assessment for predicting pustulotic arthro-osteitis in palmoplantar pustulosis based on a prospective cohort study","volume":"89","author":"Fukasawa","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2024122223541749700_llae236-B37","doi-asserted-by":"crossref","first-page":"16010","DOI":"10.1038\/s41598-019-52435-8","article-title":"Prevention of calpain-dependent degradation of STK38 by MEKK2-mediated phosphorylation","volume":"9","author":"Enomoto","year":"2019","journal-title":"Sci Rep"},{"key":"2024122223541749700_llae236-B38","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1080\/02656736.2021.2024281","article-title":"Decrease in MAP3Ks expression enhances the cell death caused by hyperthermia","volume":"39","author":"Enomoto","year":"2022","journal-title":"Int J Hyperthermia"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llae236\/59649098\/llae236.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/1\/21\/59649098\/llae236.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/1\/21\/59649098\/llae236.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,22]],"date-time":"2024-12-22T23:54:31Z","timestamp":1734911671000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/50\/1\/21\/7730002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,8]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,8,8]]},"published-print":{"date-parts":[[2024,12,23]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llae236","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,8,8]]}}}